Plain-English translation of NCT05950165 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called , which is designed to target cancer cells in non-Hodgkin lymphoma that has not responded to previous treatments or has come back. The study will test the medication at different dose levels first to find the safest and most effective dose, and later will test whether combining it with another drug called works better.
Many people with non-Hodgkin lymphoma run out of effective treatment options when their cancer stops responding to standard therapies or returns after treatment. This trial exists to explore whether this new medication could offer hope to patients who have limited other choices.
In the first part of the study, you would receive the medication as an intravenous infusion once per week for 4 weeks, then once every 3 weeks for up to 6 cycles total. Doctors would gradually increase the dose across different patient groups to find the safest level, and later participants might receive the medication combined with . You would have regular clinic visits, blood tests, and imaging scans to monitor how your lymphoma is responding and to watch for any side effects.
AI-generated summary from trial data · Sep 1, 2026 · Not medical advice
Taiwan